| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 16.9 | 18.8 | 14.1 |
| Other income | 0.4 | 0.0 | 0.1 |
| Total income | 17.2 | 18.8 | 14.1 |
| Profit before exceptional items & tax | 0.7 | 0.9 | 0.3 |
| Profit before tax | 0.7 | 0.9 | 0.3 |
| Net profit | 0.0 | 1.0 | 0.3 |
| Operating margin | 4.1% | 4.8% | 2.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +19.90% |
|---|
BSE results filing, NSE: SANDUPHQ. Figures extracted from the filing.
Sandu Pharmaceuticals Ltd: key numbers
- Share price
- ₹36.82
- Market cap
- ₹35.57 Cr
- Revenue (annual)
- ₹69.93 Cr
- Net profit (annual)
- ₹1.77 Cr
- P/E (TTM)
- 14.6×Sector 47.3×
- Promoter holding
- 37.79%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sandu Pharmaceuticals Ltd
All →Sandu Pharmaceuticals Management Change
Sandu Pharmaceuticals appointed Dr. Neeti Madan Kapre as director and Dave & Dave as statutory auditor, while announcing other board and auditor tenure changes.
Sandu Pharmaceuticals Other Announcement
Sandu Pharmaceuticals has appointed M/s. Dave & Dave as Statutory Auditors for a five-year term, following the tenure expiry of the previous auditors.
Sandu Pharmaceuticals Annual General Meeting
Sandu Pharmaceuticals Limited held its 41st Annual General Meeting on September 11, 2026, via video conferencing to transact ordinary and special business items.
Sandu Pharmaceuticals Other Announcement
Sandu Pharmaceuticals Ltd issued a letter to shareholders whose email addresses are not registered, providing the weblink to the Annual Report for FY 2026-27.
Sandu Pharmaceuticals Annual Report
Sandu Pharmaceuticals Limited has filed its 41st Annual Report for the financial year 2025-26, including the notice for the upcoming 41st Annual General Meeting.
Sandu Pharmaceuticals Annual General Meeting
Sandu Pharmaceuticals announced its 41st Annual General Meeting scheduled for September 11, 2026. The notice includes resolutions for dividend declaration and board appointments.